Domov › Diabetes mellitus 2. typu › Oklahoma
Klinické štúdie Diabetes mellitus 2. typu v štáte Oklahoma
13 štúdií pre Diabetes mellitus 2. typu hľadá účastníkov v zariadeniach v štáte Oklahoma.
Mestá v štáte Oklahoma
Oficiálny text štúdie (anglicky)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Tekton Research Oklahoma City, Oklahoma City
- South Oklahoma Heart Research Group, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07064473A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- Tekton Research Oklahoma City, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07754461A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- Hightower Clinical, Oklahoma City
- Medical Research International, LLC, Oklahoma City
- Ascension St. John - Jane Phillips Medical Center, Tulsa
Prebieha náborVítaní zdravých dobrovoľníkov
Vek 55 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT06112418A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT07743450A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
- Unity Clinical Research, Oklahoma City
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 15. 9. 2026 · NCT07340320A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT06897475A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Oklahoma City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT07662213AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Lynn Institute of Norman, Norman
Prebieha náborFáza 3
Vek 45 a viac · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT07797335A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Research Site, Norman
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 31. 8. 2026 · NCT07662109A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- University of Oklahoma Health Sciences Center, Oklahoma City
Prebieha náborFáza 3
Vek 10 až 17 · Všetky pohlavia · Aktualizované 7. 8. 2026 · NCT06739122DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
- The University of Oklahoma Health Sciences Center, Oklahoma City
Prebieha náborObservačná štúdia
Vek 8 až 15 · Všetky pohlavia · Aktualizované 7. 5. 2026 · NCT06525259Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
- Lynn Health Science Institute - Oklahoma City, Oklahoma City
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 3. 2026 · NCT07282743Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.